Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnRH antagonist start day 1 vs day 6 vs conventional GnRH agonist long protocol in PCOS patients undergoing IVF/ET
KCT0000157Phase 3Recruiting
- Sponsor
- Merck Serono
- Start
- Jun 2011
- Countries
- 1
01
Overview
Phase 3, randomised trial of relugolix in polycystic ovary syndrome (PCOS) (3 arms), sponsored by Merck Serono. Started Jun 2011; status: recruiting.
02
Drugs
relugolix
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on KCT0000157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000157.